Elucidation of lorlatinib toxicity mechanisms through GC-MS-based metabolomics
Journal of Pharmaceutical and Biomedical Analysis · 2025-11 · 265 · 117017
DOI: 10.1016/j.jpba.2025.117017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical and Biomedical Analysis, 2025-11. Verfasst von Di Niu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Jining No.1 People's Hospital, Shandong First Medical University, Jining 272000, China. Electronic address: niudi3703@163…. Hauptthemen laut MEDLINE: Metabolomics, Lactams, Lactams, Macrocyclic, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province, The Natural Science Foundation of Shandong Province, Key R&D Program of Jining.
Abstract (Originalsprache)
Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor that demonstrates superior efficacy in the treatment of non-small cell lung cancer (NSCLC). However, its toxicological profile remains insufficiently understood. In this study, we employed an untargeted metabolomics approach. Differential metabolites were identified in the hippocampus, cerebral cortex, lungs, and serum between the control and lorlatinib-treated groups of mice. Subsequently, KEGG pathway enrichment analysis was performed on these differential metabolites. The findings suggest that lorlatinib may exert toxicity by disrupting lipid metabolism, linoleic acid metabolism, niacin and nicotinamide metabolism, as well as the synthesis and metabolic pathways of multiple amino acids. This study clarifies the impact of lorlatinib exposure on metabolic profiles across various mouse tissues, identifies metabolism-related pathways linked to lorlatinib toxicity, and provides new insights into its toxicological mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Jining No.1 People's Hospital, Shandong First Medical University, Jining 272000, China. Electronic address: niudi3703@163.com.
- Translational Pharmaceutical Laboratory, Jining No.1 People's Hospital, Shandong First Medical University, Jining 272000, China. Electronic address: zhaoshiyuan94@163.com.
- Department of Clinical Pharmacy, Jining No.1 People's Hospital, Shandong First Medical University, Jining 272000, China. Electronic address: ksspharm@163.com.
- Department of Clinical Pharmacy, Jining No.1 People's Hospital, Shandong First Medical University, Jining 272000, China. Electronic address: 2277937062@qq.com.
- Department of Clinical Pharmacy, Jining No.1 People's Hospital, Shandong First Medical University, Jining 272000, China. Electronic address: 848941385@qq.com.
Förderung
- Natural Science Foundation of Shandong Province
- The Natural Science Foundation of Shandong Province
- Key R&D Program of Jining
Zitieren
APA
Niu, D., Zhao, S., Kong, S., Zhang, X., & Ma, C. (2025). Elucidation of lorlatinib toxicity mechanisms through GC-MS-based metabolomics. Journal of Pharmaceutical and Biomedical Analysis, 265, 117017. https://doi.org/10.1016/j.jpba.2025.117017
Vancouver
Niu D, Zhao S, Kong S, Zhang X, Ma C. Elucidation of lorlatinib toxicity mechanisms through GC-MS-based metabolomics. Journal of Pharmaceutical and Biomedical Analysis. 2025;265:117017. doi:10.1016/j.jpba.2025.117017
BibTeX
@article{Niu2025,
author = {Niu, Di and Zhao, Shiyuan and Kong, Shanshan and Zhang, Xue and Ma, Chunyan},
title = {Elucidation of lorlatinib toxicity mechanisms through GC-MS-based metabolomics},
journal = {Journal of Pharmaceutical and Biomedical Analysis},
year = {2025},
volume = {265},
pages = {117017},
doi = {10.1016/j.jpba.2025.117017}
}
EUVIMED